22:58 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
20:10 , Sep 22, 2017 |  BC Week In Review  |  Company News

Ultragenyx counters RegenxBio with bid for Dimension

On Sept. 18, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. In August, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire...
21:30 , Sep 18, 2017 |  BC Extra  |  Company News

Ultragenyx counters RegenxBio with bid for Dimension

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. Last month, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire Dimension in a...
18:02 , Sep 1, 2017 |  BC Week In Review  |  Company News

RegenxBio acquiring gene therapy play Dimension

RegenxBio Inc. (NASDAQ:RGNX) will acquire Dimension Therapeutics Inc. (NASDAQ:DMTX) in a stock deal. For each share held, Dimension shareholders will receive 0.1573 RegenxBio shares, which the companies say implies a value of $3.41 per Dimension...
20:28 , Aug 25, 2017 |  BC Extra  |  Company News

RegenxBio acquiring gene therapy play Dimension

RegenxBio Inc. (NASDAQ:RGNX) will acquire Dimension Therapeutics Inc. (NASDAQ:DMTX) in a stock deal. For each share held, Dimension shareholders will receive 0.1573 RegenxBio shares, which the companies say implies a value of $3.41 per Dimension...
07:00 , May 25, 2015 |  BioCentury  |  Emerging Company Profile

Dimension's intentions

With an industry veteran at the helm and its lead program partnered and paid for, Dimension Therapeutics Inc. aims to develop safer and more potent gene therapies by packaging as many gene copies into capsids...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

GlyGenix Therapeutics, Philips deal

GlyGenix will explore the feasibility of using Royal Philips' ultrasound-mediated DNA delivery technology with the biotech's glucose-6-phosphatase catalytic subunit-related protein ( G6PC , G6Pase ) plasmid DNA for glycogen storage disease Type Ia (GSD-Ia). The...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Von Gierke's disease Glucose-6-phosphatase catalytic subunit (G6PC; G6Pase); nuclear receptor coactivator 2 (NCOA2; SRC2); RAR-related orphan receptor-a (RORa) Studies in mice...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Coronary heart disease (CHD); nephropathy SNP rs560887; glucose-6-phosphatase catalytic subunit-related protein (IGRP; G6PC2) A genome-wide association study suggests that a...